Ground Breaking Technology Shows Significant Effect in Blinded Cross-Over Study

New York – July 16 2015 – New research reveals the significant glycemic improvement achieved by the ground-breaking DIAMOND technology in patients suffering from type 2 diabetes.

The research was conducted on 51 patients through a blinded, randomized, cross-over study across 48 weeks.  All patients were implanted with the device, and randomized into one of two groups: a group with the “device off” and a group with the “device on”.  Over the course of the first 24 weeks there was no notable difference between the groups.  The patients were then crossed over between the two groups. By week 48 significant improvements in glycemic levels were observed in the patients with the device turned on.

The DIAMOND technology is intended for treating patients with type 2 diabetes who are also obese. These patients are expected to benefit from the combination of significant improvement in blood glucose levels, as well as weight loss, reduction in waist circumference, and improvement in blood pressure, cholesterol and triglyceride levels.

The study was conducted with lead professor, Harold E. Lebovitz at the State University of New York Health Sciences Center at Brooklyn, New York.

Learn more about the trial here: http://www.ncbi.nlm.nih.gov/pubmed/26177957

 

 

About type 2 diabetes
Type 2 diabetes is a metabolic disorder characterized by hyperglycemia resulting from inadequate insulin secretion or insulin resistance. The most common form of diabetes, it represents 90% of all cases. Often referred to as a pandemic, it is estimated that over 400 million people worldwide are affected by diabetes, with management costs exceeding $800 billion annually.

 

About DIAMOND therapy
DIAMOND therapy is delivered via an implantable medical device which has the potential to be used as an alternative to insulin.  The safety and efficacy of DIAMOND therapy have been validated in clinical trials involving over 300 patients, including a pilot study which demonstrated a comparable effectiveness to insulin treatment, but avoiding many side-effects and the inconvenience of frequent blood tests and injections.  Designed to treat type 2 diabetes in obese patients who are refractory to oral medication, DIAMOND therapy is delivered via a small pacemaker-like device implanted in the abdomen, which delivers electrical signals to the stomach when eating, improving glycemic control and promoting weight loss.  DIAMOND has received CE mark and is approved for sale in Europe, Australia and other international markets; it is currently not approved for use in the USA.  For more information, visit www.MetaCure.com/DIAMOND.

 

About MetaCure
MetaCure, a member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients. It develops, produces and markets the DIAMOND therapy, an alternative to insulin delivered via a proprietary implantable device.  For more information, visit MetaCure.com.

 

About Hobart Group
The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs.  Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation.  Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia.  For more information, visit www.Hobart-Group.com.

 

For media enquiries
Mrs. Sharon Alon
Email: Media@MetaCure.com
Tel: +1 347-761-3342
Website: www.MetaCure.com